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	 Docetaxel	 ↓↓	 Solid	tumours	




	 Drotaverine	 ↓↓	 Antispasmodic	
































	 Dasatinib	 ↓↓	 Chronic	myeloid	leukaemia	
CYP11B2	 Height	 Spironolactone	 	 ↓↓↓↓	
Hyperaldosteronism;	Oedema;	Heart	Failure;	
Hypertension	
DBH	 Non.Pleiotropic	 	 Ascorbic	acid	 ↓	 Scurvy	
DDAH1	 Adiposity	 	 Esomeprazole	 ↓	 Peptic	ulcer	disease	
EDNRA	 CAD	 	 Ambrisentan	 ↓↓	 Pulmonary	hypertension	
ESR1	 Adiposity,	Height	 	 Dobutamine	 ↓↓	 Inotropic	support;	cardiac	stress	testing	




	 Dasatinib	 ↓↓	 Chronic	myeloid	leukaemia	

























	 Diazoxide	 ↓↓	 Hypoglycemia	
LIMK1	 Lung.function	 	 Dabrafenib	 ↓↓	 Melanoma	
MTHFR-
NPPB	














	 Bepridil	 ↓↓	 Angina(withdrawn)	





















Carvedilol	 	 ↓↓↓↓	 Hypertension;	Angina;	Heart	Failure	
YES1	 Non.Pleiotropic	 	 Dasatinib	 ↓↓	 Chronic	myeloid	leukaemia	
	
	
All	pleiotropic	associations	of	BP	GWAS	SNPs	were	extracted	and	categorised	into	groups		of	correlated	traits.	Some	SNPs	did	not	show	any	non-
BP	associations	and	were	classified	as	non-pleiotropic.		The	genes	linked	to	GWAS	SNPs	were	determined	by	proximity	to	the	SNP	and	
cardiovascular	plausibility.	Only	one	gene	per	loci	was	included.			Drug-gene	interactions	were	obtained	from	Drug	Bank	and	Comparative	
Toxicogenomics	Database	and	drug		indications	were	obtained	from	the		British	National	Formulary	and		FDA	labelled	indications.	
	
	
	
Legends	to	Figures.	
Figure	1:		Blood	pressure	regulation	–	blood	pressure	is	the	product	of	cardiac	output	and	peripheral	
vascular	resistance	and	these	are	regulated	by	a	multitude	of	factors.	This	figure	shows	the	spectrum	of	
rare	genomic	mutations	affecting	blood	pressure	by	perturbing	specific	physiological	systems.	
Additionally,	the	role	of	polygenic	variants	are	complex	and	integral	to	blood	pressure	regulation	
through	pathways	that	are	yet	to	be	characterised.	Blood	pressure	is	a	multifactorial	trait	and	the	circos	
background	plot	represents	both	the	landscape	of	genetic	variants	and	environmental	and	other	factors	
that	have	a	role	in	blood	pressure	regulation.	The	inner	circle,	represents	the	organ	specific	physiological	
pathways	that	affect	blood	pressure.	The	length	of	each	segment	is	a	relative	representation	of	known	
genetic	factors	involved	in	that	pathway.	The	outer	circle	represents	the	polygenic	background	and	
known	environmental	factors	that	influence	multiple		physiological	pathways	leading	to	the	final	blood	
pressure	phenotype.	
	
Figure	2:	Genetic	architecture	of	blood	pressure	and	hypertension.	The	circos102	plot	shows	depicts	the	
monogenic	and	polygenic	genetic	variants	identified	by	linkage,	sequencing	and	genome	wide	
association	studies.	Monogenic	variants	are	large	filled	red	circles	and	they	are	connected	to	their	
Clinical	syndromes.	The	smaller	blue,	green	and	yellow	filled	circles	are	SNPs	identified	from	genome	
wide	association	studies.	The	colour	of	the	SNPs	indicates	whether	the	best	association	of	the	SNP	was	
for	systolic,	diastolic	or	pulse	pressure.	FH	–	Familial	hyperaldosteronism;	AME	–	Apparent	
mineralocorticoid	excess;	PHA	–	Pseudohypoaldosteronim	II;	APA	–	Aldosterone	producing	adenoma;	
CAH	–	Congenital	adrenal	hyperplasia;	HTNBRACH	–	Hypertension	with	brachydactyly;	HSD3B2	-	3β-
hydroxysteroid	dehydrogenase	deficiency;	PGL1-5	–	Paraganglioma;	VHL	–	Von	Hippel	Lindau	Syndrome;	
MEN	–	Multiple	Endocrine	Neoplasia	II.	
The	top	of	the	plot	shows	pleiotropic	signals	from	PheWAS,	which	indicate	lifestyle,	environmental	and	
early	life	influences	on	blood	pressure	linked	to	the	location	of	the	pleiotropic	SNPs.	
The	histogram	on	the	outer	ring	indicates	the	number	of	pleiotropic	associations	SNPs	in	that	locus	
have.	The	taller	the	graph,	the	greater	the	number	of	pleiotropy.	
	
Figure	3:	Pleiotropic	signals	from	phenome	wide	association	studies.	The	Venn	diagrams	show	the	
number	of	blood	pressure	SNPs	that	are	significantly	associated	with	other	traits.	The	top	panel	is	the	
global	pleiotropic	landscape	of	different	phenotypic	groups	with	the	number	of	BP	SNPs	that	overlap	
with	them	shown	within	brackets.	Here	overarching	phenotypic	groups	were	condensed	from	a	range	of	
traits	that	fall	under	this	category.	More	detailed	representation	of	the	constituents	of	the	major	
phenotypic	groups	are	represented	in	the	bottom	panel	showing	the	contribution	of	individual	traits	and	
the	degree	of	pleiotropy	with	blood	pressure	and	the	level	of	overlap	between	them.	
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